NCT04623814View on ClinicalTrials.gov

the Safety, Tolerability, and Pharmacokinetics Study of HEC113995

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

August 12, 2020

Study Completion Date

August 12, 2020

Conditions
Major Depressive Disorder
Interventions
OTHER

Food

HEC113995 20mg will be taken orally fasted or with food

DRUG

HEC113995

HEC113995 will be taken orally fasted (HEC113995 10mg）or with food (HEC113995 20mg and 40mg） for 10 days

DRUG

placebo

The placebo will be administered fasted or with food for 10 days.

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04623814 - the Safety, Tolerability, and Pharmacokinetics Study of HEC113995 | Biotech Hunter | Biotech Hunter